We should be in the vanguard. We should be in the lead.
What we want to do is figure out how Congress can make it more competitive.
It is especially important that as we evaluate this legislation we consider the unintended consequences for both the pat...
We must consider the potential impact that this requirement could have on the industry.
We need to ensure that, as we work to shine a light on how drugs come to market and are priced, that we realize that the...
In that light, I believe any policies pursued by this committee must put the patient front and center.
I think Secretary Azar is onto something when he says we ought to disclose what the cost to the patient would be.
When I return home to north Texas and conduct meetings in my district office, I frequently hear the very personal storie...
I fear that this policy could lead to a sort of public shaming of companies that are trying to benefit patients.
It would be wrong for a formulary or an insurance company, anyone else, to change your patient's medication.
What I don't want to happen is that Congress overreacts.